Biotech

Biogen Inc (NASDAQ: BIIB) shares, which suffered a severe setback in early 2019 after the company's Alzheimer's program flopped, were seeing a resurgence Tuesday.  The stock fell under the psychological barrier of $300 March 21, when the company and its development partner Eisai...

The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 21.) Aprea Therapeutics Inc (NASDAQ: APRE) AVITA MED LTD/S ADR (NASDAQ: RCEL) Celgene Corporation (NASDAQ: CELG) Constellation Pharmaceuticals...

The FDA has cleared three therapies since Friday, sending shares of the sponsor companies higher Monday morning. Foamix Preps For Maiden Commercial Launch  Specialty pharma company Foamix Pharmaceuticals Ltd (NASDAQ: FOMX) said late Friday the FDA approved its Amzeeq topical foam, 4%, for...

Shares of the large-cap biopharma Seattle Genetics, Inc. (NASDAQ: SGEN) were advancing strongly Monday following a clinical trial readout from the company. Primary, Secondary Endpoints Met A pivotal Phase 2 trial dubbed HER2CLIMB that evaluated tucatinib in combination with Roche Holdings AG...

Biotech stocks saw some strength last week. Positive clinical readouts, a couple of M&A deals and hopes of drug companies clinching a broader opioid settlement agreement worked in favor of the sector. Reata Pharmaceuticals Inc (NASDAQ: RETA) was among the strong performers of the week following...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 17) Applied Therapeutics Inc (NASDAQ: APLT) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Celgene Corporation (NASDAQ: CELG) Kodiak Sciences Inc (...

InVitae Corp (NYSE: NVTA) shares have had a somewhat volatile week of trading after short seller allegations against the company prompted a bullish analyst to defend InVitae’s model. What Happened On Oct. 11, a short seller article published on Seeking Alpha accused InVitae of being the...

AstraZeneca plc (NYSE: AZN) and partner DAIICHI SANKYO/S ADR (OTC: DSNKY) announced positive news Thursday on their HER-2 targeting antibody drug conjugate, or ADC. This should come as a relief for the U.K. pharma giant, which recently flunked a late-stage non-small cell lung cancer study....

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Oct. 16.) Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN): announced a deal to be acquired by Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)....

Mirati Therapeutics Inc (NASDAQ: MRTX), a thinly traded, smid-cap oncology biotech, is on investors' radars ahead of upcoming conference presentations and data readouts. Mirati is expected to make a late-breaking presentation on its KRAS inhibitor MRTX849 at the American Association...

Johnson & Johnson (NYSE: JNJ) stock was on the rise Wednesday following better-than-expected third-quarter earnings and guidance, but analysts are mostly leery of boosting recommendations in light of a string of legal challenges the company faces. The Analysts Morgan Stanley’s...

Alexion Pharma (NASDAQ: ALXN) will buy Achillion Pharma (NASDAQ: ACHN) for the initial value of $930 million, or $6.30 per share in cash plus added contingent considerations for total potential value of $8.30 per share. Alexion will also be acquiring the cash currently on Achillion's balance...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG) Eagle Pharmaceuticals Inc (NASDAQ: EGRX) Kodiak Sciences Inc (NASDAQ: KOD) The Medicines Company (NASDAQ:...

A commercial-stage French biotech with expertise in oncology drug development is testing the IPO waters this week. The IPO Terms France-based Innate Pharma S.A. is proposing to offer 10.67 million shares in a global offering in the form of ADSs in the U.S. Each ADS represents the right to receive...

Shares of small-cap biotech Relmada Therapeutics Inc (NASDAQ: RLMD) were soaring to their highest level since 2015 following a positive clinical readout from the company.  Exciting Results  New York-based Relmada released top-line data from a Phase 2 study that evaluated its REL-1017...